Hsa-miR-15a and Hsa-miR-16-1 Expression Is Not Related to Proliferation Centers Abundance and Other Prognostic Factors in Chronic Lymphocytic Leukemia

Autor: Claudia Mannu, Anna Gazzola, Maria Antonella Laginestra, Gian Matteo Rigolin, Antonio Cuneo, Simona Righi, Stefano Pileri, Marco Luciani, Fabio Fuligni, Pier Paolo Piccaluga, Maria Ciccone, Maura Rossi, Maria Rosaria Sapienza, Claudio Agostinelli

Publikováno v: BioMed Research International, Vol 2013 (2013)
BioMed Research International

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is the commonest leukemia in adults. Here, we aimed to evaluate hsa-miR-15a/hsa-miR-16-1 expression in CLL tissues by qPCR and correlate it with the other clinicopathological features and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d499cea1d0e0ff67294b1f04805b26e
https://doi.org/10.1155/2013/715391

FIRMA MOLECOLARE E SUOI USI COME AGENTE DIAGNOSTICO

Autor: PICCALUGA, PIER PAOLO, AGOSTINELLI, CLAUDIO, LAGINESTRA, MARIA ANTONELLA, GAZZOLA, ANNA, Pileri S, Rossi M, Fuligni F, De Leo A.

Firma molecolare basata su espressione genica ad uso diagnostico per linfomi a cellule t periferiche nodali

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______4094::86b5a9e780ec71c08366f2aaf7b3bd6b
http://hdl.handle.net/11585/423855

Pathobiology of Hodgkin Lymphoma

Autor: Simona Righi, Anna Gazzola, Maria Antonella Laginestra, Elena Sabattini, Francesco Bacci, Carlo A. Sagramoso-Sacchetti, Claudio Agostinelli, Claudia Mannu, Pier Paolo Piccaluga, Maria Rosaria Sapienza, Maria Teresa Sista, Claudio Tripodo, Stefano Pileri, Maura Rossi

Publikováno v: Advances in Hematology
Università degli Studi di Palermo-IRIS
Advances in Hematology, Vol 2011 (2011)

Despite its well-known histological and clinical features, Hodgkin's lymphoma (HL) has recently been the object of intense research activity, leading to a better understanding of its phenotype, molecular characteristics, histogenesis, and possible me

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb234f1a27198b026e4651e2256508e3
http://europepmc.org/articles/PMC3021869

Bitter Taste Receptor Agonist Denatonium Inhibits Stemness Characteristics in Hematopoietic Stem/Progenitor Cells.

Autor: Pensato V; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.; Institute of Hematology and Center for Hemato-Oncology Research, Department of Medicine and Surgery, University and Hospital of Perugia, Perugia, Italy., Laginestra MA; Laboratory of Experimental Oncology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Falvo P; Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.; Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy., Orecchioni S; Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.; Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy., Talarico G; Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.; Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy., De Marchi E; Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy., Bruno S; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy., Mongiorgi S; Department of Biomedical and Neuromotor Sciences - DIBINEM, University of Bologna, Bologna, Italy., Mitola G; Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.; Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy., Bertolini F; Laboratory of Hematology-Oncology, European Institute of Oncology IRCCS, Milan, Italy.; Onco-Tech Lab, European Institute of Oncology IRCCS and Politecnico di Milano, Milan, Italy., Adinolfi E; Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy., Cavo M; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli' Bologna, Italy., Curti A; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli' Bologna, Italy., Salvestrini V; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli' Bologna, Italy.

Publikováno v: Stem cells (Dayton, Ohio) [Stem Cells] 2024 Jan 13; Vol. 42 (1), pp. 42-54.

IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.

Autor: Setola E; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy. elisabetta.setola@ieo.it.; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy. elisabetta.setola@ieo.it., Benini S; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Righi A; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Gamberi G; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Carretta E; IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Ferrari C; Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Avnet S; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Palmerini E; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy., Magagnoli G; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Gambarotti M; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Lollini PL; Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy., Cesari M; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy., Cocchi S; Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Paioli A; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy., Longhi A; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy., Scotlandi K; Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Laginestra MA; Experimental Oncology Laboratory, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Donati DM; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy., Baldini N; Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.; Biomedical Science and Technologies Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy., Ibrahim T; Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, IRCCS Istituto Ortopedico Rizzoli, Via Pupilli 1, Bologna, 40136, Italy.

Publikováno v: BMC cancer [BMC Cancer] 2023 Sep 26; Vol. 23 (1), pp. 907. Date of Electronic Publication: 2023 Sep 26.